In this study we retrospectively analyzed 179 patients with endometrial carcinoma or atypical endometrial hyperplasia treated with GnRHa plus LNG-IUD/aromatase inhibitors. The gene discussed is CYP19A1; the disease is atypical endometrial hyperplasia.